Direct-Acting Antiviral Agents for HCV Infection.
作者信息
Premkumar Madhumita, Dhiman Radha K
机构信息
Department of Hepatology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
出版信息
J Clin Exp Hepatol. 2018 Mar;8(1):1-2. doi: 10.1016/j.jceh.2018.01.002. Epub 2018 Mar 26.
Abstract
摘要
相似文献
1
Direct-Acting Antiviral Agents for HCV Infection.用于丙型肝炎病毒感染的直接抗病毒药物
J Clin Exp Hepatol. 2018 Mar;8(1):1-2. doi: 10.1016/j.jceh.2018.01.002. Epub 2018 Mar 26.
2
Occult hepatitis C virus infection in hemodialysis patients who achieved a sustained virological response to directly acting antiviral drugs: is it a concern?直接作用抗病毒药物治疗后获得持续病毒学应答的血液透析患者中的隐匿性丙型肝炎病毒感染：是否需要关注？
Int Urol Nephrol. 2024 Jan;56(1):217-222. doi: 10.1007/s11255-023-03621-1. Epub 2023 May 20.
3
Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents.在直接作用抗病毒药物时代，基于他汀类药物（3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂）治疗丙型肝炎病毒（HCV）感染相关疾病
F1000Res. 2016 Feb 26;5:223. doi: 10.12688/f1000research.7970.3. eCollection 2016.
4
Reasons for not commencing direct-acting antiviral treatment despite unrestricted access for individuals with HIV and hepatitis C virus: a multinational, prospective cohort study.尽管艾滋病毒和丙型肝炎病毒感染者可不受限制地获得直接抗病毒治疗，但仍未开始治疗的原因：一项跨国前瞻性队列研究。
Lancet Public Health. 2023 Apr;8(4):e294-e304. doi: 10.1016/S2468-2667(23)00056-7.
5
Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.埃及慢性丙型肝炎病毒感染患者直接抗病毒药物治疗前后的男性性功能障碍。
J Sex Med. 2019 Mar;16(3):402-409. doi: 10.1016/j.jsxm.2019.01.309.
6
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.直接作用抗病毒疗法治疗肾移植受者丙型肝炎病毒感染。
Kidney Int. 2018 Mar;93(3):560-567. doi: 10.1016/j.kint.2017.10.024. Epub 2018 Jan 9.
7
Timing of Hepatitis C Virus Treatment in Liver Transplant Candidates in the Era of Direct-acting Antiviral Agents.直接抗病毒药物时代肝移植候选者中丙型肝炎病毒治疗的时机
J Clin Transl Hepatol. 2017 Dec 28;5(4):363-367. doi: 10.14218/JCTH.2017.00007. Epub 2017 Sep 14.
8
[Application of direct antiviral drugs in special patients with HCV infection].[直接抗病毒药物在特殊丙型肝炎病毒感染患者中的应用]
Zhonghua Gan Zang Bing Za Zhi. 2018 Apr 20;26(4):316-320. doi: 10.3760/cma.j.issn.1007-3418.2018.04.017.
9
Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis.混合性冷球蛋白血症综合征和冷球蛋白血症性肾小球肾炎患者的丙型肝炎病毒感染治疗
Hemodial Int. 2018 Apr;22 Suppl 1:S81-S96. doi: 10.1111/hdi.12649.
10
Treating paediatric hepatitis C in the era of direct-acting antiviral agents.直接作用抗病毒药物时代的儿童丙型肝炎治疗。
Liver Int. 2021 Jun;41(6):1189-1200. doi: 10.1111/liv.14810. Epub 2021 Mar 8.
引用本文的文献
1
Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy.肝纤维化：治疗靶点与药物治疗进展
Front Cell Dev Biol. 2021 Sep 21;9:730176. doi: 10.3389/fcell.2021.730176. eCollection 2021.
2
HCV Infection in Thalassemia Syndromes and Hemoglobinopathies: New Perspectives.地中海贫血综合征和血红蛋白病中的丙型肝炎病毒感染：新视角
Front Mol Biosci. 2020 Jan 30;7:7. doi: 10.3389/fmolb.2020.00007. eCollection 2020.
本文引用的文献
1
Advances in HCV and Cryoglobulinemic Vasculitis in the Era of DAAs: Are We at the End of the Road?直接抗病毒药物时代丙型肝炎病毒与冷球蛋白血症性血管炎的进展：我们已走到尽头了吗？
J Clin Exp Hepatol. 2018 Mar;8(1):81-94. doi: 10.1016/j.jceh.2017.11.012. Epub 2017 Dec 7.
2
Effect of Sofosbuvir Plus Daclatasvir in Hepatitis C Virus Genotype-4 Patients: Promising Effect on Liver Fibrosis.索磷布韦联合达卡他韦对丙型肝炎病毒基因4型患者的疗效：对肝纤维化有显著效果。
J Clin Exp Hepatol. 2018 Mar;8(1):15-22. doi: 10.1016/j.jceh.2017.06.006. Epub 2017 Jun 30.
3
Impact of Direct Acting Antiviral Therapy for Treatment of Hepatitis C Genotypes 1, 3 and 4: A Real Life Experience from India.直接作用抗病毒疗法治疗丙型肝炎基因1型、3型和4型的疗效：来自印度的真实病例经验
J Clin Exp Hepatol. 2018 Mar;8(1):7-14. doi: 10.1016/j.jceh.2017.06.003. Epub 2017 Jun 19.
4
Safety and Efficacy of Sofosbuvir and Daclatasvir for Hepatitis C Virus Infection in Patients with β-Thalassemia Major.索磷布韦和达卡他韦治疗重型β地中海贫血合并丙型肝炎病毒感染的安全性和有效性
J Clin Exp Hepatol. 2018 Mar;8(1):3-6. doi: 10.1016/j.jceh.2017.06.002. Epub 2017 Jun 23.
5
Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?慢性丙型肝炎：仿制药的效果与品牌药一样好吗？
J Clin Exp Hepatol. 2017 Sep;7(3):253-261. doi: 10.1016/j.jceh.2017.08.003. Epub 2017 Sep 23.
6
Generic Direct Acting Antivirals in Treatment of Chronic Hepatitis C Infection in Patients of Thalassemia Major.通用型直接抗病毒药物治疗重型地中海贫血患者慢性丙型肝炎感染
J Clin Exp Hepatol. 2017 Sep;7(3):172-178. doi: 10.1016/j.jceh.2017.08.002. Epub 2017 Aug 23.
7
Direct-acting antivirals for chronic hepatitis C.用于慢性丙型肝炎的直接作用抗病毒药物。
Cochrane Database Syst Rev. 2017 Sep 18;9(9):CD012143. doi: 10.1002/14651858.CD012143.pub3.
8
Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection.随机临床试验：索磷布韦和来迪派韦用于输血依赖型地中海贫血合并丙型肝炎病毒1型或4型感染患者
Aliment Pharmacol Ther. 2017 Aug;46(4):424-431. doi: 10.1111/apt.14197. Epub 2017 Jun 29.
9
Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.使用印度可获得的通用直接作用抗病毒药物治疗丙型肝炎的成本效益。
PLoS One. 2017 May 17;12(5):e0176503. doi: 10.1371/journal.pone.0176503. eCollection 2017.
10
Treatment of chronic hepatitis C with direct-acting antivirals in patients with β-thalassaemia major and advanced liver disease.在重型β地中海贫血和晚期肝病患者中使用直接作用抗病毒药物治疗慢性丙型肝炎。
Br J Haematol. 2017 Jul;178(1):130-136. doi: 10.1111/bjh.14640. Epub 2017 Apr 25.
Zotero 插件